Advanced

Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele

Bentmar Holgersson, Magdalena LU ; Ruhayel, Yasir LU ; Karlsson, Magnus LU ; Giwercman, Aleksander LU ; Bjartell, Anders LU ; Ohlsson, Claes; Mellström, Dan; Ljunggren, Östen; Haghsheno, Mohammad-Ali and Damber, Jan-Erik, et al. (2017) In Cancer Causes and Control 28(3). p.227-233
Abstract

Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios... (More)

Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele. Results: The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45–0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47–1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51–0.90; p = 0.008). Conclusions: Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Androgen receptor, Genetic variants, Prostate cancer
in
Cancer Causes and Control
volume
28
issue
3
pages
227 - 233
publisher
Springer
external identifiers
  • scopus:85011923808
  • wos:000394986000005
ISSN
0957-5243
DOI
10.1007/s10552-017-0859-1
language
English
LU publication?
yes
id
f00fbcbf-624c-42b4-a209-e54e2c002941
date added to LUP
2017-02-27 14:29:33
date last changed
2018-01-07 11:52:58
@article{f00fbcbf-624c-42b4-a209-e54e2c002941,
  abstract     = {<p>Background: In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis. Methods: Using data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele. Results: The 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45–0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47–1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51–0.90; p = 0.008). Conclusions: Swedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.</p>},
  author       = {Bentmar Holgersson, Magdalena and Ruhayel, Yasir and Karlsson, Magnus and Giwercman, Aleksander and Bjartell, Anders and Ohlsson, Claes and Mellström, Dan and Ljunggren, Östen and Haghsheno, Mohammad-Ali and Damber, Jan-Erik and Giwercman, Yvonne},
  issn         = {0957-5243},
  keyword      = {Androgen receptor,Genetic variants,Prostate cancer},
  language     = {eng},
  number       = {3},
  pages        = {227--233},
  publisher    = {Springer},
  series       = {Cancer Causes and Control},
  title        = {Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele},
  url          = {http://dx.doi.org/10.1007/s10552-017-0859-1},
  volume       = {28},
  year         = {2017},
}